MAPK1IP1L

Across TCGA pan-cancer cohorts, MAPK1IP1L Mutation is linked to patient survival in 4 of 34 cancer types, making it a survival-associated MAPK1IP1L data layer compared with 25 for mass-spec protein and 6 for mass-spec protein.

The strongest signal is observed in lung squamous cell carcinoma (LUSC), where higher MAPK1IP1L Mutation is associated with worse overall survival. In most high-consensus cancer types, elevated MAPK1IP1L expression acts as an unfavorable survival marker.

LUSC, PRAD, and UCEC are the cancer types where MAPK1IP1L Mutation most reproducibly stratifies survival.

Mutation survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
LUSC	OS	Median	All	0.159	0.659	.020	12	view →
PRAD	DFS	Median	All	0.085	0.774	<.001	6	view →
UCEC	OS	Median	IV	0.231	0.592	.036	6	view →
SKCM	OS	Median	All	0.399	0.783	.021	3	view →

Pink = unfavorable, green = favorable. Showing the 4 strongest of 4 lineages.

MAPK1IP1L–LUSC (OS)

Open the LUSC breakdown →